Get started
MERCK & CO.MERCK & CO.MERCK & CO.

MERCK & CO.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Bonds

4MRKX trade ideas

MRK MarkThere was a time when Nen Ideas were 110% purely experimental. Back to the old school drawing board thinking about the potential futures for this stock and ignoring the fact that the future might not be predictable in a rational Universe of Unknown Variables and Undetermined events. I look at the current price formation and ask 3 questions. 1. Is this a corrective construct that will lead to the popping of the price on the up? 2. Will we still be in a correction formation in the coming trading days, that can see the unfolding of a bearish wave before things settle into a more clear picture? 3. Do this prediction attempts are even relevant? Considering any time some big unforseen news can just shake the markets out of any detectable pattern? I have designed some elements in this project as milestones or anchor points not reference points to see how random they are, or if the stock price evolution might be random or if the words that I type are actually almost random, considering there is no difference between the way that I write or the way that I draw something on TW. Last 2 waves are the ones I am more interested in. A potential bull run after Earnings, maybe if it reaches the bottom plank, or a possible correction started from the marked price level above... I have no clue if Merck will pop one way or another out of the current formation which looks highly intriguing, but something might be boiling in preparation for some resolution of the current picture (the squeezed price between the trend line and the top resistance arc zone. This is experimental.
NYSE:MRK
by nen
3
Despite Beating Q2 Expectations Merck Stock Slides KEY TAKEAWAYS: - Merck & Co. revised its full-year adjusted EPS projection to $7.94-$8.04, down from $8.53-$8.65. - Second-quarter sales of its flagship drug, Keytruda, rose 16% year-over-year. - The company beat Q2 expectations on both revenue and profit metrics. Shares of Merck & Co. ( NYSE:MRK ) plummeted on Tuesday after the pharmaceutical giant slashed its full-year adjusted profit guidance. Despite delivering solid second-quarter earnings and revenue, the outlook revision overshadowed the company’s performance, causing a significant dip in its stock price. Earnings and Revenue Beat Expectations In the second quarter, Merck reported earnings per share (EPS) of $2.14 on revenue of $16.11 billion, surpassing analysts' expectations of $2.05 EPS and $15.88 billion in revenue, as per Visible Alpha. The company’s pharmaceutical division contributed $14.41 billion to the revenue, marking a 7% increase from the previous year. Merck’s flagship cancer drug, Keytruda, was a standout performer with sales surging 16% to $7.27 billion. Another notable contribution came from Winrevair, a pulmonary arterial hypertension drug approved by the FDA in March, which generated $70 million in sales. Guidance Cut and Stock Reaction Despite the strong quarterly performance, Merck lowered its full-year adjusted EPS guidance to a range of $7.94-$8.04, down from the prior range of $8.53-$8.65. This adjustment reflects the impact of a one-time charge of approximately $1.3 billion, or $0.51 per share, related to the acquisition of EyeBio. The market reacted sharply to this news, with Merck's shares dropping over 9% to $115.91 by late morning on Tuesday. The stock experienced its most significant loss in three years, falling as much as 7.7%, largely due to concerns over the reduced profit outlook and issues with Gardasil shipments in China. Challenges and Strategic Moves Merck’s reduced profit forecast was partly influenced by lower-than-expected sales of its Gardasil HPV vaccine in China. Chief Executive Officer Rob Davis highlighted a “surprising” decrease in Gardasil shipments to China due to issues with a third-party distributor. This unexpected downturn in one of the world’s most populous markets raised concerns about the long-term sales targets for Gardasil. Merck ( NYSE:MRK ) has been proactive in seeking new growth avenues as its blockbuster drug Keytruda faces future pricing pressures. Last year, Merck spent nearly $11 billion to acquire Prometheus Biosciences Inc., a maker of treatments for autoimmune disorders. Additionally, Merck entered a deal with Daiichi Sankyo Co. worth up to $22 billion to collaborate on novel cancer medicines. Updated Revenue Forecast and Future Prospects Despite the lowered EPS guidance, Merck increased its full-year revenue forecast by $200 million at the median, to a range of $63.4 billion to $64.4 billion. The company’s next significant product, Winrevair, has shown promise, bringing in $70 million in its first full quarter on the U.S. market, exceeding analysts' expectations. Adjusted earnings for Q2 were $2.28 per share, beating analysts’ average estimate by 11 cents. Revenue also outperformed expectations, bolstered by a 16% increase in Keytruda sales. BMO analyst Evan Seigerman remarked on Merck’s consistent commercial performance, noting that the Winrevair launch exceeded even the highest expectations. He stated, “Another quarter of the same story. Merck commercial outperformance remains steady.” Technical Outlook As of the present time, the stock of Merck ( NYSE:MRK ) has experienced a considerable decline of 9.45%. The Relative Strength Index (RSI) is currently at 30.09, indicating the stock is approaching the oversold region. Furthermore, a detailed inspection of the daily price chart reveals the presence of a long bearish Harami candlestick pattern, which is widely recognized as a significant reversal pattern in technical analysis. Conclusion Merck’s stock slide following the guidance cut underscores the market’s sensitivity to profit projections, even in the face of strong quarterly results. The company’s robust performance in Q2, driven by Keytruda and the successful launch of Winrevair, demonstrates Merck’s potential for growth despite current challenges. However, the reduced profit outlook and issues with Gardasil shipments in China highlight the hurdles Merck must navigate to maintain its market position and investor confidence.
NYSE:MRKShort
by DEXWireNews
Citadel Advisors invested in Merck to drive growthCitadel Advisors, along with other institutional investors, has increased its stake in Merck & Co., indicating a solid market interest as the company's stock currently appears undervalued. During the second quarter of 2024, Citadel Advisors acquired 1.25 million shares of Merck & Co., contributing to a rise in the stock price as smaller investors followed suit, bolstering their investments in the pharmaceutical giant. Merck & Co. continues to experience robust sales growth from its flagship cancer drug, Keytruda. However, investors must also weigh potential risks, notably the impending expiration of Keytruda's patent protection in the US by 2028. This event could lead to increased competition from biosimilar drugs, potentially impacting Merck's revenue streams. To mitigate this, Merck & Co. is urged to diversify and strengthen its pharmaceutical portfolio beyond immuno-oncology to drive sustainable growth. Technical analysis of Merck & Co. Inc. (NYSE: MRK) Evaluating the potential trading opportunities based on the current technical landscape of Merck & Co.'s stock: Timeframe : Daily (D1) Current Trend : the stock is currently in a global uptrend that began at the end of 2021 Resistance Level : 133.50 USD Support Level : 121.00 USD Potential Downtrend Target : if a downtrend develops, a potential downside target could be 99.50 USD Short-Term : if the uptrend persists and the stock surpasses the resistance at 133.50 USD, a short-term target could be set at 140.00 USD Medium-Term : with continued upward momentum, the stock price might target 150.00 USD Investors should continue to monitor Merck & Co., especially given the significant institutional investment and the strategic challenges ahead. The company's ability to innovate and expand its product offerings will be crucial in maintaining its competitive edge in the pharmaceutical industry. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65.68% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:MRK
by RoboMarkets
Merck’s Tight Consolidation Near HighsMerck has moved sideways after breaking out in January. Could traders see potential for more upside in the second half? The first pattern on today’s chart is the range between the closing prices on March 26 and March 28. This channel is less than $7 wide, or approximately 5 percent of the drugmaker’s share price. Could that narrowness give way to expansion? Second, this range is above the previous all-time high of $119.65 from May 2023. Such consolidation above the earlier peak could suggest that new support has been established above old resistance. Third, MRK violated support on May 30 but quickly rebounded. The resulting false breakdown is a potentially bullish reversal pattern. Next, the 50-day simple moving average (SMA) is above the 100-day SMA. Both are above the 200-day SMA. That configuration, with faster SMAs above slower SMAs, could resemble a longer-term uptrend. (Also notice last week's bounce at the 100-day SMA.) Finally, our 2 MA Ratio custom script is in the lower study. It shows that the 8-day exponential moving average (EMA) recently crossed above the 21-day EMA. That may reflect an uptrend over the shorter term. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NYSE:MRK
by TradeStation
1
(MRK) - Navigating Through Market Signals and IndicatorsAbstract: We perform a comprehensive technical analysis of Merck & Co., Inc. (NYSE: MRK) by dissecting its latest price movements, chart patterns, and technical indicators. This analysis is aimed at shedding light on the potential future price trajectory for MRK, integrating both traditional technical analysis tools and advanced indicators to inform speculative positions. Price Action and Chart Patterns: The recent price activity of MRK demonstrates a consolidation phase with a slight bearish inclination. The stock has been traversing within a narrow range following a significant uptrend, as evidenced by the series of higher highs and higher lows from November 2023 to February 2024. The latest candles are positioned within the Ichimoku cloud on the daily chart, which hints at a potential trend ambiguity in the short term. However, the presence of a 'doji' candle followed by a minor bullish candle may suggest an indecision in the market sentiment that precedes a possible trend reversal. Ichimoku Cloud: The Ichimoku Kinko Hyo, a pivotal component in our analysis, indicates a transition phase. With the price oscillating within the cloud (known as 'Kumo'), we are in a state of equilibrium, where the bullish and bearish forces are balanced. A decisive breakout above the cloud could signal a bullish continuation, while a drop below the cloud would align with a bearish forecast. Fibonacci Retracement Levels: Using the swing high at $133.10 and swing low at $110.65, we observe that the price recently retraced to and slightly surpassed the 0.236 level at $129.83 before recoiling. This behavior showcases the market's respect for Fibonacci retracement levels, often viewed as potential reversal zones. Moving Averages: The 50-day and 200-day Moving Averages (MAs) are trending upwards, confirming the general bullish bias in the medium to long term. The recent price action around the 50-day MA suggests this level as a dynamic support. Volume and Volume-Based Indicators: The On-Balance Volume (OBV) shows a steady rise, which typically indicates accumulative behavior and can be a precursor to a positive price breakout. This is in congruence with the increasing volume bars seen in recent trading sessions. Relative Strength Index (RSI) and Moving Average Convergence Divergence (MACD): The RSI hovers around the 50 mark, which is considered neutral territory, although it has descended from overbought conditions. The MACD line is about to cross above the signal line, and the histogram is moving upwards towards the zero line, both suggesting that upward momentum may be gaining traction. Price Target Speculation: Assuming the bullish scenario where the price breaks above the Ichimoku cloud, our speculative price targets are set at the Fibonacci levels of $133.10 (0 level) as the first target, and a breach above this level could lead the stock towards the all-time high at $139.00. Alternatively, a bearish downturn would initially aim for the support around the $122 level, coinciding with the 0.786 Fibonacci retracement and the top boundary of the cloud. Earnings Report: With the next earnings report due in 8 days, market participants should exercise caution as the release could significantly impact the stock's volatility. Market Sentiment and Conclusion: MRK's stock performance is at a crossroads, with technical indicators providing mixed signals. Investors should monitor the key levels indicated by the Ichimoku Cloud and Fibonacci retracements. While the upward momentum could be resurfacing, as suggested by the MACD and OBV, the forthcoming earnings report may serve as a catalyst for a definitive price direction. Prudent traders may consider setting tight stop-loss orders to mitigate risk in the face of potential earnings-induced volatility.
NYSE:MRK
by AxiomEx
Merck Pulls Back from Record HighDrugmaker Merck has been pushing to new highs, and now it’s pulled back. The first pattern on today’s chart is a pair of gaps. On February 1, earnings and revenue beat estimates. The second jump on March 27 followed approval of a lung-disease drug. Both of those gaps pushed the stock to record highs. Next, MRK held last year’s previous all-time high in mid-March. Has old resistance become new support? Third, the past week saw prices test below the April 26 close of $125.52 but keep closing above it. Is support now established at a higher level? Next, the 50-day simple moving average (SMA) had a “golden cross” above the 200-day SMA in late January. That may suggest the long-term trend has grown more bullish. Prices are now trying to stabilize at the rising 50-day SMA. Some dip buyers may see an opportunity at that intermediate-term trend indicator. Finally, MRK reports earnings on April 25. It’s also an active underlier in the options market, with TradeStation data showing average daily volume of 29,500 contracts per day in the last month. Traders seeing potential of an earnings move could find it a potential candidate for a vertical spread. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means. Margin trading involves risks, and it is important that you fully understand those risks before trading on margin. The Margin Disclosure Statement outlines many of those risks, including that you can lose more funds than you deposit in your margin account; your brokerage firm can force the sale of securities in your account; your brokerage firm can sell your securities without contacting you; and you are not entitled to an extension of time on a margin call. Review the Margin Disclosure Statement at www.TradeStation.com .
NYSE:MRK
by TradeStation
Merck's New Drug for Rare High Blood Pressure Approved by FDAMerck & Co., ( NYSE:MRK ) has achieved a significant milestone in the realm of medical innovation with the recent approval of its groundbreaking treatment for a rare and life-threatening form of high blood pressure. The approval of the drug, known as sotatercept and to be marketed as Winrevair in the US, by the Food and Drug Administration (FDA) marks a pivotal moment not only for Merck but also for patients suffering from pulmonary arterial hypertension (PAH). Let's delve deeper into the implications of this milestone and its potential impact on both Merck and the medical landscape. Addressing a Critical Need: PAH, characterized by dangerously elevated blood pressure in the lungs, poses a significant health threat to thousands of Americans, particularly among the elderly, women, and Black individuals. Despite existing therapies, many patients fail to respond adequately, highlighting the urgent need for innovative treatment options. Merck's Winrevair offers a promising solution, providing hope for improved outcomes and quality of life for PAH patients. A Game-Changer in PAH Treatment: Experts have hailed Merck's drug as potentially groundbreaking in the treatment of PAH. With its demonstrated efficacy in clinical trials, including significant improvements in patients' ability to walk and perform daily activities, Winrevair represents a paradigm shift in PAH management. Moreover, its approval for self-administration offers added convenience and flexibility for patients, further enhancing its appeal and accessibility. Strategic Implications for Merck: The approval of Winrevair comes at a critical juncture for Merck as it navigates the evolving pharmaceutical landscape. With the looming expiration of market exclusivity for its blockbuster drug Keytruda, Merck has been seeking innovative therapies to diversify its portfolio and sustain long-term growth. Winrevair's potential to generate multibillion-dollar revenues and fill the gap left by Keytruda underscores its strategic importance for Merck's future success. Market Response and Outlook: Investors have responded positively to the news of Winrevair's approval, driving a surge in Merck's stock price. Analysts have revised their sales projections upwards, reflecting confidence in the drug's commercial potential and its ability to address unmet medical needs. Moreover, ongoing research into Winrevair's long-term benefits and potential expansion into new patient populations bodes well for its sustained growth and market penetration.
NYSE:MRKLong
by DEXWireNews
Riding the Bull: Merck & Co. ($MRK)Potential Upside ?Right now, the trend for NYSE:MRK looks positive, meaning it's going up, so it's a good time to take advantage of that momentum. The current value zone, where it's reasonably priced, is between $119 and $124. It's suggested to set a stop loss at $116, meaning if the stock drops below that, it's a signal to sell to limit potential losses. NYSE:MRK is currently below its perceived value, and there's potential for it to reach new all-time highs (ATH). So, it's a good opportunity to ride the wave and possibly make some gains.
NYSE:MRKLong
by ImmaculateTony